Novel Mechanism of Action for Hydralazine: Induction of Hypoxia-Inducible Factor-1 &agr;, Vascular Endothelial Growth Factor, and Angiogenesis by Inhibition of Prolyl Hydroxylases

The vasodilator hydralazine, used clinically in cardiovascular therapy, relaxes arterial smooth muscle by inhibiting accumulation of intracellular free Ca2+ via an unidentified primary target. Collagen prolyl hydroxylase is a known target of hydralazine. We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating O2-dependent prolyl hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action. Hydralazine induced rapid and transient expression of HIF-1&agr; and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation. Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1&agr;, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity. In vivo, hydralazine induced HIF-1&agr; and VEGF protein in tissue extracts and elevated plasma VEGF levels. In sponge angiogenesis assays, hydralazine increased stromal cell infiltration and blood vessel density versus control animals. Thus, hydralazine activates the HIF pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype. This represents a novel mechanism of action for hydralazine and presents HIF as a potential target for treatment of ischemic disease.

[1]  David R. Williams,et al.  Metal binding by pharmaceuticals. Part 4. A comparative investigation of the interaction of metal ions with hydralazine, prizidilol and related compounds , 2005, Agents and Actions.

[2]  Christian Frelin,et al.  Hypoxia Up-regulates Prolyl Hydroxylase Activity , 2003, Journal of Biological Chemistry.

[3]  R. Johnson,et al.  HIF-1α controls extracellular matrix synthesis by epiphyseal chondrocytes , 2003, Journal of Cell Science.

[4]  R. Johnson,et al.  HIF-1alpha controls extracellular matrix synthesis by epiphyseal chondrocytes. , 2003, Journal of cell science.

[5]  D. Henderson-smart,et al.  Drugs for treatment of very high blood pressure during pregnancy. , 2013, The Cochrane database of systematic reviews.

[6]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[7]  D. Richardson,et al.  The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.

[8]  K. Kangawa,et al.  Intravenous Adrenomedullin in Myocardial Function and Energy Metabolism in Patients After Myocardial Infarction , 2002, Journal of cardiovascular pharmacology.

[9]  M. Oehler,et al.  Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis , 2002, Oncogene.

[10]  L. Chao,et al.  Human adrenomedullin gene delivery protects against cardiovascular remodeling and renal injury , 2001, Peptides.

[11]  R. Hendel,et al.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. , 2001, American heart journal.

[12]  M. Gassmann,et al.  HIF‐1 is expressed in normoxic tissue and displays an organ‐specific regulation under systemic hypoxia , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[14]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[15]  J. M. Arbeit,et al.  Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. , 2001, Genes & development.

[16]  A. Gurney,et al.  Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery , 2001, British journal of pharmacology.

[17]  James L. Park,et al.  Heme oxygenase-1 protects against vascular constriction and proliferation , 2001, Nature Medicine.

[18]  G. Semenza Hypoxia-Inducible Factor 1: Control of Oxygen Homeostasis in Health and Disease , 2001, Pediatric Research.

[19]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[20]  V. Fuster,et al.  Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist. , 2001, Archives of internal medicine.

[21]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[22]  G. Taraboletti,et al.  Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. , 2000, The American journal of pathology.

[23]  M. Noble,et al.  An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. , 2000, Human molecular genetics.

[24]  N. Ali,et al.  Activation of particulate guanylate cyclase by adrenomedullin in cultured SV-40 transformed cat iris sphincter smooth muscle (SV-CISM-2) cells. , 2000, Cellular signalling.

[25]  J. Waltenberger,et al.  A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. , 1999, Biochemical and biophysical research communications.

[26]  P. Pagliaro,et al.  New insights into nitric oxide and coronary circulation. , 1999, Life sciences.

[27]  A. Latimer,et al.  Activation of particulate guanylyl cyclase by endothelins in cultured SV-40 transformed cat iris sphincter smooth muscle cells. , 1998, Life sciences.

[28]  W. Risau,et al.  Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Nielsen-Kudsk,et al.  Hydralazine-induced vasodilation involves opening of high conductance Ca2+-activated K+ channels. , 1998, European journal of pharmacology.

[30]  K. Rehse,et al.  New NO donors with antithrombotic and vasodilating activities, Part 24. Hydrazine derivatives. , 1998, Archiv der Pharmazie.

[31]  G. Semenza,et al.  Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[32]  G. Semenza,et al.  Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[33]  N. Abraham,et al.  Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis , 1998, Journal of cellular biochemistry.

[34]  A. Choi,et al.  Regulation of heme oxygenase-1 gene expression in vascular smooth muscle cells by nitric oxide. , 1997, The American journal of physiology.

[35]  M. Yanagisawa,et al.  Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery. , 1997, European journal of pharmacology.

[36]  S. Rajagopalan,et al.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. , 1996, The Journal of clinical investigation.

[37]  U. Elkayam,et al.  Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. , 1995, Journal of the American College of Cardiology.

[38]  Y. Hirata,et al.  Autocrine Regulation of the Endothelin‐1 Gene in Rat Endothelial Cells , 1995, Journal of cardiovascular pharmacology.

[39]  J. Caro,et al.  Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[40]  A. Logan,et al.  Angiogenesis , 1993, The Lancet.

[41]  N. Bleehen,et al.  Comparative effects of hydralazine on perfusion of KHT tumor, kidney and liver and on renal function in mice. , 1992, International journal of radiation oncology, biology, physics.

[42]  E. Darwish,et al.  Management of severe preeclampsia detected in early labor by prostaglandin A1 or dihydralazine infusions. , 1991, American journal of obstetrics and gynecology.

[43]  R. Fisker,et al.  Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues. , 1991, Acta oncologica.

[44]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[45]  S. Pinnell,et al.  A paradoxical effect of hydralazine on prolyl and lysyl hydroxylase activities in cultured human skin fibroblasts. , 1985, Archives of biochemistry and biophysics.

[46]  M. Jacobs Mechanism of action of hydralazine on vascular smooth muscle. , 1984, Biochemical pharmacology.

[47]  K. Hermsmeyer,et al.  Effect of hydralazine on tension and membrane potential in the rat caudal artery. , 1983, The Journal of pharmacology and experimental therapeutics.

[48]  C. Desch,et al.  Hydralazine and Isosorbide Dinitrate: Comparative Central and Regional Hemodynamic Effects When Administered Alone or in Combination , 1981, Circulation.

[49]  P. Reece,et al.  Kinetics of hydralazine and its main metabolites in slow and fast acetylators , 1980, Clinical pharmacology and therapeutics.

[50]  S. Wolfe,et al.  Hydralazine-induced disturbances in collagen biosynthesis. , 1972, Biochimica et biophysica acta.